Brief: Fusion Announces U.S. FDA Clearance Of IND For FPI-2059
23/06/2022 12:46
June 23 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR
FPI-2059, AN INVESTIGATIONAL SMALL MOLECULE-BASED
RADIOPHARMACEUTICAL TARGETING SOLID TUMORS EXPRESSING NTSR1
Source text for Eikon: ID:nPn2V1CYNa
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary